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ABSTRACT

2

A higher intake of foods rich in flavonoids such as quercetin can reduce the risk of

3

cardiovascular disease. Enzymatically modified isoquercitrin (EMIQ®) has a bioavailability

4

17-fold higher than quercetin aglycone and has shown potential cardiovascular disease

5

moderating effects in animal studies. The present study aimed to determine if acute ingestion

6

of EMIQ® improves endothelial function, blood pressure, and cognitive function in human

7

volunteers at risk of cardiovascular disease. Twenty-five participants (12 males, 13 females)

8

with at least one cardiovascular disease risk factor completed this randomized, controlled,

9

crossover study. In a random order, participants were given EMIQ® (2 mg aglycone

10

equivalent)/kg body weight or placebo alongside a standard breakfast meal. Endothelial

11

function, assessed by flow mediated dilatation (FMD) of the brachial artery was measured

12

before and 1.5 hrs after intervention. Blood pressure (BP), arterial stiffness, cognitive

13

function, BP during cognitive stress and measures of quercetin metabolites, oxidative stress

14

and markers of nitric oxide (NO) production were assessed post-intervention. After

15

adjustment for pre-treatment measurements and treatment order, EMIQ® treatment resulted in

16

a significantly higher FMD response compared to the placebo [0.60%, 95% CI: 0.03, 1.17

17

(p=0.04)]. Plasma concentrations of quercetin metabolites were significantly higher

18

(p<0.001) after EMIQ® treatment compared to the placebo. No changes in blood pressure,

19

arterial stiffness, cognitive function, or biochemical parameters were observed. In this

20

human intervention study, the acute administration of EMIQ® significantly increased

21

circulating quercetin metabolites and improved endothelial function. Further clinical trials are

22

required to assess whether health benefits are associated with long-term EMIQ®

23

consumption.

24
25
26
27
28
29
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INTRODUCTION:

31

There is mounting evidence from both cohort studies and clinical trials that an increased

32

intake of plant foods, specifically those rich in flavonoids, can reduce the risk of

33

cardiovascular disease (1). Quercetin (in its glycosylated form) is the most commonly

34

consumed flavonoid compound within the flavonol subclass (2). The main dietary contributors

35

to quercetin intake include tea, apples, onions, and broccoli (3).

36

Evidence for the health promoting effects of quercetin comes primarily from animal and in

37

vitro studies (4). In a randomized-controlled cross-over study of men and women, apples with

38

skin significantly reduced systolic blood pressure, improved endothelial function and

39

increased plasma nitric oxide (NO) (5). These apples with skin provided 184 mg of quercetin

40

and 180 mg of (−)-epicatechin while the apple flesh only (control) provided less than 5 mg of

41

quercetin and (−)-epicatechin. Previous studies using both pure quercetin aglycone (1095 mg)

42

(6)

43

endothelial function. This may be due to in part to the bioavailability of the quercetin

44

interventions.

45

Quercetin in foods is usually found in its glycosylated form, with the presence and position of

46

the sugar moiety influencing the site and extent to which it is absorbed (9). The bioavailability

47

of quercetin glucosides can be enhanced by enzymatic α-oligoglucosylation of this sugar

48

moiety (10). Enzymatically modified isoquercitrin (EMIQ®) is a water-soluble glucoside of

49

quercetin produced by the deglycosylation and subsequent α-oligoglucosylation of rutin (10).

50

Plasma concentrations of quercetin metabolites have been shown to be approximately 2-3

51

times higher after the consumption of EMIQ® in comparison to isoquercitrin (quercetin-3-O-

52

glucoside) and its bioavailability is 17-fold higher than that of quercetin (10; 11).

53

EMIQ® has been shown to suppress the increase in systolic BP observed in spontaneously

54

hypertensive rats, (12) and decrease oxidative stress in a mouse model of atherosclerosis (13).

55

EMIQ® is approved in Japan as a food additive and is safe for human consumption. Human

56

trials carried out over a 12-week period indicate a significant reduction in body fat (14). The

57

effects of EMIQ® on vascular and cognitive function have yet to be investigated.

58

Therefore, the aim of the present study was to determine if acute ingestion of EMIQ®

59

improves endothelial function, blood pressure, and cognitive function in human volunteers at

60

risk of cardiovascular disease.

and quercetin glucoside supplementation (50 – 400 mg) (7; 8) have shown no effect on

4
61

SUBJECTS AND METHODS:

62

Participants

63

Twenty-five eligible men and women, aged between 50 and 70 years, were recruited by

64

newspaper advertisement from the general population of Perth, Western Australia (Figure 1).

65

These volunteers attended a screening appointment within the University of Western

66

Australia, School of Biomedical Sciences, located in the Medical Research Foundation

67

building at Royal Perth Hospital. The screening appointment consisted of an

68

electrocardiograph, a standard medical history questionnaire, and the measurement of height,

69

weight, body mass index (BMI) and BP. Finally, a blood sample was taken for measurement

70

of fasting serum total cholesterol, HDL-cholesterol (HDL-C), triglycerides (TG), LDL-

71

cholesterol (LDL-C), and glucose. Volunteers were included in the study if they had at least

72

one of the following risk factors for CVD: systolic BP between 120 mmHg and 160 mmHg,

73

fasting plasma glucose between 5.6 mM and 6.5 mM, total cholesterol between 5 mM and 8

74

mM or a waist circumference >94 cm for men or >80 cm for women. Exclusion criteria

75

included a BMI <18 or >35 kg/m2; a systolic BP ≤100 or ≥160 mmHg; a diastolic BP ≤50 or

76

≥90 mmHg; diagnosed diabetes; fasting plasma glucose concentrations ≥6.5 mmol/L; use of

77

BP lowering or cholesterol lowering medication; alcohol intake >210 g per week for women

78

and >280 g per week for men; current or recent (within previous 6 months) significant weight

79

loss or gain (>6% of body weight); actively trying to lose weight; current or recent (<12

80

months) smoking; history of cardiovascular or peripheral vascular disease; psychiatric or any

81

other major illnesses; and women were lactating, pregnant or wishing to become pregnant

82

during the study.

83

The study was carried out in accordance with the Declaration of Helsinki and was approved

84

by the University of Western Australia Human Research Ethics Committee (Approval

85

number RA/4/1/9260). All participants provided written informed consent before inclusion in

86

the study. The trial was registered with the Australian New Zealand Clinical Trials Registry

87

(ACTRN12617001202358).

88

Study design

89

This acute, randomized, controlled crossover trial was conducted between September 2017

90

and June 2018. Participants were required to visit the department three times (one practice

91

visit and two study visits). The practice visit involved the completion of a selection of
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cognitive function tests designed to induce cognitive stress (see description below) three

93

times, in order to control for practice effects and to allow familiarization with procedure. The

94

practice day data were not included in any analyses. Participants were required to fast for 12

95

hrs (water allowed ad libitum) prior to each subsequent study visit. These two visits were

96

separated by at least 7 days to ensure that there were no carry-over treatment effects.

97

Participants were instructed to have the same meal the night before, not to consume any

98

alcohol for 24 hrs prior to the visit and not to take any medication or undergo any exercise on

99

the morning of their visit. Endothelial function was assessed before and 1.5 hrs post-

100

intervention. A blood pressure measurement was taken prior to and every 10 min for 80 min

101

post treatment. Measurements of arterial stiffness were taken 2 hrs post-intervention.

102

Participants completed the selection of cognitive function tests 2.5 hrs post-intervention,

103

during which blood pressure was measured every 2 min. Finally, a blood sample was taken

104

by venipuncture 3.5 hrs post-intervention.

105

Intervention

106

Participants were randomly assigned to one of two treatment orders generated using a

107

pseudorandom number generator (https://www.randomizer.org/). The EMIQ® was prepared

108

by San-Ei Gen F.F.I., Incorporated (Osaka, Japan). The active treatment consisted of 4.89 mg

109

EMIQ® (2 mg aglycone equivalent)/kg body weight (10) plus ½ teaspoon of maltodextrin and

110

1½ tablespoons of Cottee’s Raspberry flavoured cordial mixed with 250 mL water. The

111

placebo treatment was ½ teaspoon of maltodextrin and 1½ tablespoons of cordial mixed with

112

250 mL water. The cordial was used to mask the taste and the colour of the EMIQ®. Both

113

treatments were given with a standardised breakfast of 2 pieces of white bread and cheese.

114

Participants and all researchers performing the tests and analysing the results were blinded to

115

the treatment.

116

Assessment of endothelial function

117

In order to assess endothelial function, flow-mediated dilatation (FMD) of the brachial artery

118

was calculated by a trained ultrasonographer, dedicated to the research protocol and blinded

119

to the interventions used. Participants were studied in a quiet, temperature-controlled room

120

(21 to 25 °C). Participants rested in a supine position for 20 min prior to the initiation of the

121

FMD measurement. The right arm was extended and supported comfortably on a foam mat.

122

For the ultrasound, a 12-MHz transducer connected to a Philips CX50 Ultrasound Machine
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was clamped in position over the brachial artery, 5 to 10 cm proximal to the antecubital

124

crease. After a baseline artery diameter recording of 1 min, a blood pressure cuff placed

125

around the left forearm was inflated to 200 mmHg. After 5 min the cuff was released,

126

inducing reactive hyperaemia. The brachial artery image was recorded for 4 min (240

127

seconds) post-cuff deflation to assess FMD. Images were downloaded for retrospective

128

analysis. Analysis of FMD was performed using a semi-automated edge detection software

129

(Vascular Research Tools, Medical Imaging Applications LLC, Coralville IA), which

130

automatically calculates the brachial artery diameter, corresponding to the internal diameter.

131

Responses were calculated as the percentage change in brachial artery diameter from

132

baseline, at 10 second intervals, for 240 seconds after cuff deflation.

133

Measurement of blood pressure and arterial stiffness

134

Blood pressure measurements were taken using a Dinamap 1846SX/P oscillometric recorder

135

(Critikon, Tampa, FL, USA) attached to the non-dominant arm with participants in a seated

136

position. Following a 10 min rest, one BP measurement was taken immediately prior to

137

treatment consumption. BP was then measured every 10 min post-treatment consumption for

138

80 min (9 measurements in total).

139

Office BP, central diastolic BP, and arterial stiffness were assessed using the SphygmoCor

140

Xcel (AtCor Medical, Sydney, Australia). Following a 5 min rest in a supine position, BP

141

measurements were taken on three occasions at 1 min intervals, the first measurement was

142

discarded and the second and third measurements were averaged. Arterial stiffness was

143

determined by measuring augmentation Index (AIx) using the Sphygmocor Xcel as described

144

previously (15) and was standardised to a heart rate of 75 bpm (AIx75).

145

Cognitive stress test and blood pressure

146

A selection of cognitive function tests designed to induce cognitive stress using the

147

Computerised Mental Performance Assessment System (COMPASS, BPNRC, Newcastle

148

Upon Tyne, UK) was used. This series of tests, described in detail previously (16), comprised

149

of two computerized serial subtraction tasks (Serial Threes and Serial Sevens) and a Bakan

150

Rapid Visual Information Processing task (RVIP), each repeated three times. Briefly, for the

151

Serial Three and Serial Seven subtraction tasks, participants were asked to continuously

152

subtract three or seven from a random starting number between 800 and 999. This task lasted

153

for two min and both the number of correct responses and the total number of subtractions
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completed were recorded. For the RVIP task, participants were asked to identify when three

155

odd or three even digits appeared consecutively in series of single digit numbers presented at

156

a rate of 100 per min. This task lasted for five min and both the number of correct responses

157

and the average response time were recorded. Participants rested for 20 min prior to and 15

158

min after the cognitive testing, which took approximately 30 min. For the duration of this

159

task (65 min total), blood pressure was measured every 2 min with a Dinamap 1846SX/P

160

oscillometric recorder (Critikon, Tampa, FL, USA) attached to the non-dominant arm of

161

participants in a seated position.

162

Plasma analyses

163

Plasma samples, obtained 3.5 hrs post-intervention by venepuncture, were collected into

164

EDTA tubes with added butylated hydroxytoluene and immediately centrifuged at 5000 x g,

165

at 4°C for 5 min. One 2 mL aliquot of plasma was kept on liquid nitrogen for immediate

166

analysis of nitrogen oxides (NOx) and the remaining plasma was stored at -80°C until

167

analysis.

168

Quercetin metabolites

169

Plasma quercetin metabolites were measured by liquid chromatography/tandem mass

170

spectrometry (LCMSMS) as described previously (7). Briefly, plasma (250 µL) collected in

171

EDTA was incubated for 2 hrs with β-glucuronidase enzyme. As β-glucuronidase has both

172

glucuronidase and sulfatase activity, but is unable to enzymatically cleave methyl conjugates,

173

isorhamnetin (O-methylated quercetin) was measured. Following solid phase extraction,

174

quercetin aglycone and isorhamnetin were measured on a Thermo Scientific TSQ Quantum

175

Ultra Triple Quadrupole LCMS System (ThermoFisher Scientific, Waltham, MA, USA).

176

Calibration curves for quercetin and isorhamnetin with the fisetin as the internal standard

177

were used for quantification.

178

Measurement of plasma total nitrogen oxides (NOx)

179

The concentrations of total NOx (nitric oxide, nitros(yl)ated species and nitrite) in plasma

180

were determined using a previously described gas phase chemiluminescence assay (17). Blood

181

was collected into N-ethylmaleimide (10 mmol/L) and EDTA (2 mM), mixed and centrifuged

182

at 3000 x g (5 min, 4°C). Fresh plasma was kept on ice in the dark and analysed within 1 hr.

183

Antifoam (200 µL) was added prior to injection into the radical purger containing potassium
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iodide (0.125 g) and iodine (0.05 g) in water (2.5 mL) / glacial acetic acid (7.5 mL) at room

185

temperature. Plasma NOx was quantified by the NO signal peak area of samples against a

186

nitrite standard (300 µL, 0.5 µM NaNO2-). Quantification of NO released by the redox

187

reactions occurred by its chemiluminescence reaction with ozone using the Nitric Oxide

188

Analyzer (CLD66, Eco Physics, Sweden).

189

NO2 and NO3

190

Nitrate (NO3) and nitrite (NO2) concentrations were measured using gas

191

chromatography/mass spectrometry (GCMS) as described previously (18), with N15 labelled

192

NO3 and NO2 internal standards.

193

Glucose

194

Plasma glucose was measured using a fully automated analyser (Architect ci8200/c16000

195

Analyser).

196

F2-isoprostanes

197

Systemic oxidative stress was determined by measuring plasma F2-isoprostane concentrations

198

as described previously (19). Briefly, F2-isoprostane concentrations were calculated in pmol/L

199

from ratio of the peak areas for the m/z 569 and m/z 573 ions, with a deuterium labelled

200

internal standard, 8-iso-Prostaglandin F2α-d4.

201

Statistics

202

Sample size was calculated with FMD as the primary endpoint. Assuming a within-subject

203

correlation of r=0.25, 24 pre-intervention measures, 24 post-intervention measures, and a

204

within group SD of 6%, a sample size of 25 subjects would provide more than 80% power at

205

alpha=0.05 to detect a difference of 0.85% in FMD. Treatment effects for post-intervention

206

FMD were obtained using linear mixed models with adjustment for treatment order, the pre-

207

treatment FMD curve, and the time since cuff release with time included as a categorical

208

variable (0 to 240 seconds at 10 second intervals). In order to allow the treatment effect to

209

differ over time, we also included a treatment x time interaction term. The subject identifier

210

was included as a random intercept. Assessment of post-treatment BP was similar to that for

211

FMD, with time included as a categorical variable (0 to 80 minutes at 10-minute intervals).

212

When assessing the effect of EMIQ® on the BP during the cognitive stress test, we
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additionally adjusted for the rest-period BP. For all other outcomes, treatment effects were

214

obtained using linear mixed models with adjustment for treatment order. Statistical analyses

215

were performed using STATA/IC 14.2 (StataCorp LLC).

216
217

RESULTS:

218

Baseline data

219

Recruitment began on 25th September 2017 and the study concluded on 12th June 2018.

220

Twenty-five participants (12 males, 13 females) completed the study (Figure 1). The baseline

221

characteristics of the study participants are shown in Table 1.

222

Endothelial function

223

Data from one participant was excluded prior to statistical analysis as the clarity of the FMD

224

image was poor. The observed mean percentages of FMD for 24 participants, between 0 and

225

240 seconds at 1.5 hrs post-intervention, are presented in Figure 2. Overall, FMD after the

226

EMIQ® treatment was significantly higher when compared to control [adjusted mean

227

difference=0.60%, 95% CI: 0.03, 1.17; p=0.040].

228

Blood pressure and arterial stiffness

229

Mean systolic BP and diastolic BP, measured immediately before treatment (time=0) and

230

then every 10 min for 80 min, are shown in Figure 3. There was no significant difference

231

between EMIQ® and placebo for post-treatment systolic BP (p=0.916) or diastolic BP

232

(p=0.073). Similarly, there was no difference for MAP (p=0.188) or heart rate (p=0.290).

233

There was no significant difference between treatments for mean systolic BP, diastolic BP,

234

central diastolic pressure, MAP, heart rate, or AIx75, measured 2 hrs post-treatment (Table

235

2).

236

Cognitive stress test and blood pressure

237

There were no significant effects associated with the EMIQ® treatment on any of the

238

cognitive stress test outcomes, nor on BP measurements taken during the cognitive stress

239

tests (Tables 3 and 4).
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Plasma analyses

241

Plasma concentrations of quercetin aglycone and isorhamnetin were significantly higher

242

(p<0.001) after the ingestion of EMIQ® compared to the placebo (Table 3). There was no

243

significant difference in plasma glucose, NOx, NO2, NO3, or F2-isoprotanes between EMIQ®

244

and placebo treatments.

245
246

DISCUSSION:

247

This is the first study to investigate the acute effects of an enzymatically-modified

248

isoquercitrin compound on measures of vascular health, blood pressure and cognitive

249

function in humans. In this randomised controlled cross-over study, the acute administration

250

of EMIQ® significantly increased plasma quercetin metabolites and improved endothelial

251

function. No changes in blood pressure, arterial stiffness, cognitive function, blood pressure

252

during cognitive stress or biochemical parameters were observed.

253

In the present study plasma concentrations of quercetin aglycone and isorhamnetin were

254

significantly higher after the ingestion of EMIQ® compared to the placebo. Previously, the

255

plasma concentration of conjugated quercetin metabolites has been shown to reach a maximal

256

level at approximately 1.5 h after intake of EMIQ® (10). For this reason, our primary outcome,

257

endothelial function, was assessed 1.5 hrs post-intervention.

258

Endothelial dysfunction, defined as an impairment in endothelium-dependent relaxation, is

259

implicated in prehypertension, hypertension, atherosclerosis, and stroke (20; 21), and is

260

associated with an increased risk of cardiovascular disease (22; 23). The results of the present

261

study suggest that EMIQ® improves postprandial endothelial function. In two previous

262

studies, acute quercetin administration (1095 mg quercetin aglycone (6); and doses of

263

quercetin-3-O-glucoside ranging from 50 - 400 mg (7)) had no effect on FMD. In the study by

264

Larson et al, FMD was measured 10 hrs post-quercetin aglycone administration, the time at

265

which quercetin metabolites were shown to peak in the plasma (6). The pharmacokinetics of

266

quercetin aglycones and EMIQ are very different; in the present study FMD was measured

267

1.5 hrs post-intervention, at the time quercetin metabolites have been shown to peak in the

268

plasma following EMIQ administration (10). Quercetin-3-O-glucoside has been shown to peak

269

in the plasma between 1.5 and 3 hrs post-intervention; in our previous study (7), FMD was
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measured 1 hr post-intervention. The differences in study design and the form in which the

271

quercetin was administered make the direct comparison to the present study difficult. Another

272

important discrepancy in study design is that EMIQ was administered alongside a meal in the

273

present study, likely influencing the effect of quercetin on endothelial function (24; 25). Overall,

274

FMD in the present study was relatively poor as we recruited participants with at least one

275

risk factor for cardiovascular disease. Although the improvement observed was subtle

276

(0.66%), if sustained it could have important clinical implications as a 1% increase in FMD is

277

associated with a 13% lower risk of cardiovascular events (RR: 0.87, 95% CI: 0.83- 0.91) (23).

278

Evidence suggests that quercetin can improve endothelial health through NO-mediated

279

vasorelaxant activity as well as through the prevention of oxidant induced endothelial

280

dysfunction (4). An acute increase in plasma NO status has been observed after both a high-

281

flavonoid apple intervention (17) and quercetin (200 mg) intervention (26). In the present study

282

we did not observe any increase in plasma NOx, or the end products of NO metabolism, NO3

283

and NO2. This may have been due to the timing of our blood sample, which was 1.5 hrs after

284

the measurement of endothelial function, and 3.5 hrs post-intervention. Changes in NO are

285

likely to be transient, and because of the difficulty in detecting small changes in NO, the

286

timing of the measurement is likely to be critical.

287

In our previous randomized clinical trial with healthy men and women, improvements in BP

288

were also observed with the concomitant increase in nitric oxide status and FMD, after intake

289

of flavonoid-rich apples (17). In a meta-analysis of randomized controlled trials, significant

290

reductions in both systolic BP (−3.04 mm Hg, 95% CI: −5.75, −0.33, p=0.028) and diastolic

291

BP (−2.63 mm Hg, 95% CI: −3.26, −2.01, p<0.001) were seen following quercetin

292

supplementation (27). Furthermore, in spontaneously hypertensive rats, EMIQ® administered

293

at a dose of 26 mg/kg/d suppressed the increase in systolic BP more effectively than

294

quercetin aglycone (12). In the present study we observed no effect of EMIQ® on post-

295

treatment BP nor on BP during the cognitive stress test. This lack of effect may be due to the

296

dose given; in the aforementioned meta-analysis there was only a significant effect on BP

297

when quercetin was administered at doses greater than 500 mg/day (27). Additionally, the

298

health status of the participants may have played a role as a decrease in systolic BP following

299

quercetin supplementation is generally seen in hypertensive individuals (28; 29; 30), not in pre-

300

hypertensive or normotensive individuals (6; 30; 31; 32; 33; 34).
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Many functions of the endothelium are affected under oxidative stress, including endothelial

302

cell apoptosis (35) and adhesion of inflammatory cells (36), initiating the development of

303

atherosclerosis. Quercetin may decrease oxidative stress through the stimulation of protective

304

defences and repair systems (37). In apolipoprotein E (apoE)–deficient atherogenic mice,

305

EMIQ® supplementation for 14 weeks significantly suppressed aortic and aortic sinus

306

atherosclerotic lesion areas and decreased levels of 4-hydroxy-2-nonenal, a marker of

307

oxidative stress (13). In the present study we observed no acute changes in levels of plasma F2-

308

isoprostanes, an in vivo biomarker of oxidative stress, following the EMIQ® intervention. It

309

may be that long-term interventions are required to observe changes in biomarkers of

310

oxidative stress. Evidence that quercetin may impede the development of CVD by

311

moderating oxidative stress is stronger in animal studies than human studies (4).

312

There is evidence that flavonols, the flavonoid subclass to which quercetin belongs, can

313

reduce the risk of type 2 diabetes (T2D). This comes from an observational study which

314

found that each 2.5- fold increase in flavonol intake was associated with a 26% lower

315

incidence of T2D (38), and a meta-analysis demonstrating a significant reduction in fasting

316

plasma glucose (difference in mean = −0.18 mmol/L; 95% CI: −0.29, −0.08), following

317

flavanol intake (39). However, fasting plasma glucose was not significantly lower in any of the

318

studies with a quercetin intervention. In the present study we saw no acute effect of EMIQ®

319

on plasma glucose. Given that the study population was relatively normoglycemic, this may

320

be better investigated in a hyperglycemic population.

321

Evidence that quercetin can improve cognitive function comes wholly from animal studies (40;

322

41; 42)

323

derivative on cognitive function in humans. We saw no significant effects of EMIQ® on any

324

measures of cognitive function in the present study. This warrants further investigation;

325

future studies could consider a long-term intervention and a broader range of cognitive

326

function measurements.

327

Strengths of the present study are that any inter-subject variability was accounted for by our

328

cross-over study design and adjustments for baseline measurements of FMD controlled for

329

day to day variability. There are, however, several limitations: firstly, only the primary

330

outcome was measured before and after the intervention. Secondly, the study was only

331

powered to detect a change in the primary outcome meaning that we may have been

332

underpowered to detect changes in secondary outcomes. So as not to affect the measurement

. To our knowledge this is the first study to examine the acute effects of a quercetin
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of any other outcomes, the blood sample was taken 1.5 hrs after the measurement of FMD

334

(3.5 hrs post-intervention). Additionally, this study only investigated one dose of EMIQ®,

335

with the primary outcome measured at only one time-point.

336

In this human intervention study, the acute administration of EMIQ® significantly increased

337

circulating quercetin metabolites and improved postprandial endothelial function. The

338

addition of EMIQ® to commercially available foods and beverages may have positive effects

339

on vascular function. The potential health benefits associated with regular consumption

340

warrants investigation in longer term randomised controlled trials.

341
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TABLES
Table 1. Baseline characteristics of study participants
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Characteristic

Mean ± SD

Age (years)

64.1 ± 6.3

Weight (kg)

77.6 ± 14.9

2

BMI (kg/m )

27.0 ± 3.7

Systolic BP (mmHg)

128.6 ± 15.3

Diastolic BP (mmHg)

73.6 ± 8.4

Total cholesterol (mM)

5.6 ± 1.0

Triglyceride (mM)

1.0 ± 0.3

Low- density lipoprotein cholesterol (mM)

3.7 ± 0.8

High-density lipoprotein cholesterol (mM)

1.5 ± 0.4

Fasting plasma glucose (mM)

5.2 ± 0.5

Creatinine (mM)

67.9 ± 10.3
2

86 ± 7.2

eGFR (mL/min/1.73 m )
n=25; males=12, females=13
BP, blood pressure.

Table 2. Pulse wave analysis
EMIQ®

Control

p-value

Systolic BP (mmHg)

129.3 ± 3.2

130.9 ± 3.2

0.489

Diastolic BP (mmHg)

73.8 ± 1.8

74.1 ± 1.8

0.702

Central DP (mmHg)

74.3 ± 1.8

75.0 ± 1.8

0.518

MAP (mmHg)

88.9 ± 2.1

89.8 ± 2.1

0.455

HR (bpm)

55.9 ± 1.7

57.3 ± 1.7

0.281

AIx75 (%)

13.9 ± 2.0

13.2 ± 2.0

0.635

Results are presented as means ± sd (n=25). P-values for treatment effect were
obtained using linear mixed models with adjustment for treatment order. BP,
blood pressure; MAP, mean arterial pressure; PR, pulse rate.
Table 3. Cognitive function measurements
EMIQ®

Control

p-value

18

Serial 3 subtractions total

25.1 ± 9.0

25.2 ± 9.7

0.710

Serial 3 subtractions correct

27.0 ± 8.7

26.8 ± 9.4

0.701

Serial 7 subtractions total

19.1 ± 7.1

18.6 ± 7.9

0.569

Serial 7 subtractions correct

16.3 ± 7.7

16.4 ± 7.7

0.595

RVIP correct

54.1 ± 22.5

53.5 ± 22.4

0.299

RVIP response time (msec)

559.8 ± 57.8

551.8 ± 56.9

0.210

Cognitive test measurements, 2.5 hours post consumption of EMIQ® or placebo
treatment. Results are presented as means ± sd (n=23). P-values for treatment
effect were obtained using linear mixed models with adjustment for treatment
order and time.

Table 4. Blood pressure during cognitive stress testing
EMIQ®

Control

p-value

Systolic BP (mmHg)

129.8 ± 18.0

125.2 ± 19.9

0.468

Diastolic BP (mmHg)

72.1 ± 10.1

73.3 ± 14.4

0.510

MAP (mmHg)

94.8 ± 12.4

93.4 ± 15.0

0.466

PR (bpm)

63.3 ± 10.1

65.8 ± 15.6

0.728

Results are presented as means ± sd (n=25). Blood pressure was measured every 2
minutes for 34 minutes (17 measures total). P-values for treatment effect were
obtained using linear mixed models with adjustment for treatment order, time and
blood pressure during pre-test rest period. BP, blood pressure; MAP, mean arterial
pressure; PR, heart rate.

Table 5. Plasma analyses
EMIQ®

Control

p-value
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Glucose (mmol/L)

4.7 ± 0.1

4.7 ± 0.1

0.994

NOx (nM NO2)

36.1 ± 6.8

36.3 ± 7.1

0.979

NO3 (µM)

29.9 ± 1.8

30.9 ± 1.8

0.587

NO2 (µM)

2.5 ± 0.2

2.8 ± 0.2

0.263

F2-Isoprostanes (pmol/L)

540.7 ± 33.5

517.2 ± 33.5

0.510

Quercetin aglycone (nM)

144.9 ± 12.3

12.6 ± 12.3

<0.001

Isorhamnetin (nM)

245.5 ± 16.5

41.7 ± 16.5

<0.001

Measurements of plasma glucose, NOx, nitrate (NO3), nitrite (NO2), F2isoprostanes, and quercetin metabolites, 3 hours post consumption of EMIQ® or
placebo treatment. Results are presented as means ± sd (n=25). P-values for
treatment effect were obtained using linear mixed models with adjustment for
treatment order.

FIGURES
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Figure 1. Participant flow diagram.
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®

Figure 2. Acute changes in flow-mediated dilatation (FMD) over 240 s measured 1.5 h postintervention. Results are presented as means (n=24). P-values for treatment effect were
obtained using linear mixed models with adjustment for treatment order, time, and baseline
(pre-treatment) FMD. Over the time course there was a significant difference between
interventions (p=0.040). EMIQ®, Enzymatically-Modified Isoquercitrin.
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®

Figure 3. Acute changes in systolic and diastolic blood pressure over 80 minutes
immediately post-intervention. Treatment was given immediately after the first measurement
at time=0. Results are presented as means ± sd error bars (n=25). P-values for treatment
effect were obtained using linear mixed models with adjustment for treatment order and time.
Over the time course there was no significant difference between interventions (systolic,
p=0.916; diastolic, p=0.073). EMIQ®, Enzymatically Modified Isoquercitrin.
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